Published in Ann Intern Med on January 01, 2002
Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface (2010) 2.69
Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation (2010) 1.58
Roles for VEGF in the adult. Microvasc Res (2007) 1.48
Delivery of sphingosine 1-phosphate from poly(ethylene glycol) hydrogels. Biomacromolecules (2006) 1.20
Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett (2010) 1.08
Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis. Pharm Res (2009) 1.07
Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev (2007) 1.03
A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol (2007) 1.01
Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol (2010) 0.95
Aberrant angiogenesis: The gateway to diabetic complications. Indian J Endocrinol Metab (2012) 0.92
Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood (2005) 0.91
In vivo electroporation mediated gene delivery to the beating heart. PLoS One (2010) 0.90
New vectors and strategies for cardiovascular gene therapy. Curr Gene Ther (2007) 0.87
Ceramide-activated phosphatase mediates fatty acid-induced endothelial VEGF resistance and impaired angiogenesis. Am J Pathol (2014) 0.85
Expansion of microvascular networks in vivo by phthalimide neovascular factor 1 (PNF1). Biomaterials (2008) 0.84
Comparison of left ventricular electromechanical mapping and left ventricular angiography: defining practical standards for analysis of NOGA maps. Tex Heart Inst J (2003) 0.84
Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools. Tissue Eng (2007) 0.83
Restenosis and therapy. Int J Vasc Med (2012) 0.83
Microtopographical effects of natural scaffolding on cardiomyocyte function and arrhythmogenesis. Acta Biomater (2010) 0.81
Phthalimide neovascular factor 1 (PNF1) modulates MT1-MMP activity in human microvascular endothelial cells. Biotechnol Bioeng (2009) 0.80
Tumour angiogenesis: the relevance to surgeons. Ann R Coll Surg Engl (2006) 0.79
Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther (2012) 0.79
Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model. Nanomedicine (2014) 0.78
Controlled Angiogenesis in Peptide Nanofiber Composite Hydrogels. ACS Biomater Sci Eng (2015) 0.78
The mechanical or electrical induction of medullary angiogenesis: will it improve sternal wound healing? Tex Heart Inst J (2004) 0.76
Pro-angiogenic potential of human chorion-derived stem cells: in vitro and in vivo evaluation. J Cell Mol Med (2013) 0.75
A Renewed Emphasis on Therapeutic Angiogenesis Research for CAD. Biotechnol Healthc (2007) 0.75
Angiogenic growth factors in myocardial infarction: a critical appraisal. Heart Fail Rev (2017) 0.75
Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation (2003) 5.20
Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation (2002) 3.65
Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation (2002) 2.84
Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation (2003) 2.82
Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation (2003) 1.87
VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest (2003) 1.84
Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation (2002) 1.61
Postnatal recapitulation of embryonic hedgehog pathway in response to skeletal muscle ischemia. Circulation (2003) 1.47
Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation (2002) 1.43
Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation (2004) 1.26
Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res (2002) 1.17
Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation (2002) 1.08
Age-dependent VEGF expression and intraneural neovascularization during regeneration of peripheral nerves. Neurobiol Aging (2004) 1.01
Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. Arterioscler Thromb Vasc Biol (2002) 0.97
Functional ephrin-B2 expression for promotive interaction between arterial and venous vessels in postnatal neovascularization. Circulation (2005) 0.97
Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci (2003) 0.96
One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol (2003) 0.93
Transcutaneous ultrasound augments naked DNA transfection of skeletal muscle. Mol Ther (2002) 0.92
Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol (2005) 0.91
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther (2007) 0.89
Endothelial recovery: the next target in restenosis prevention. Circulation (2003) 0.89
Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther (2002) 0.87
Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia. Vasc Med (2005) 0.87
Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation (2005) 0.83
Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J Mol Med (Berl) (2005) 0.81
Oncogenic ras induces premature senescence in endothelial cells: role of p21(Cip1/Waf1). Basic Res Cardiol (2002) 0.78
Angiogenic gene therapy: pre-clinical studies and phase I clinical data. Kidney Int (2002) 0.75